NepRx Gets Patent For Peptide Aimed At Gastrointestinal Tract
KALAMAZOO - NephRx Corporation Wednesday announced the issuance of U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis and other diseases of the gastrointestinal tract. This new patent follows an NX002 patent for inflammatory bowel disease issued earlier this year. Previously, NephRx reported that NX002